Combination Therapy for Gout: When Two Medicines Beat One

Gout hands you two problems at once, and one pill almost never covers both.

The first problem is the joint that is swollen and screaming tonight. The second is the uric acid that put crystals there in the first place. Anti-inflammatory medicines handle the first, urate-lowering medicines handle the second, and they work on completely separate machinery, which is why they are so often used together.

Think of a flare as a fire in one room and high uric acid as the faulty wiring behind the wall. You can put the fire out, and you should. But if you never touch the wiring, another fire is only a matter of time. Combination therapy deals with both. The guideline sets the target for the wiring job at a serum urate below 6 mg/dL, because that is the level at which crystals stop forming and start to dissolve¹.

For most people, the first combination they meet is not two heavy-hitting drugs. It is one urate-lowering medicine, usually allopurinol, which is the first-line choice for nearly everyone including people with kidney disease², paired with a small daily dose of something anti-inflammatory for the opening stretch.

In the first weeks and months after you start lowering your uric acid, flares often get more frequent, not less. As the level in your blood drops, older crystals that had settled quietly in your joints begin to shift and dissolve, and a moving crystal is exactly what your immune system panics over. The medicine is doing its job, loudly.

The fix is to ride out that phase with a low-dose anti-inflammatory alongside the urate-lowering drug, rather than stopping. The American College of Rheumatology strongly recommends continuing this prophylaxis for three to six months rather than less, with more time if flares are still happening³. That is the logic of the starting combination: cover the joint while the real repair gets underway underneath.

Flares can still arrive while you are on urate-lowering therapy, especially in the early months. The medicine has not failed, and quitting it would be the wrong response. This is why flare medicine stays within reach.

Keep your urate-lowering pill going, at the same dose, and treat the flare on top of it with whatever your clinician has chosen. All three first-line flare options, low-dose colchicine, an NSAID, or a short course of a steroid, are strongly recommended and none is clearly the winner⁴. Which one suits you depends on your kidneys, your stomach, your heart, and what else you take.

The one thing not to do is stop and restart your urate-lowering therapy around a flare. Those swings push your uric acid up and down, and a swinging level is itself a flare trigger. Steady beats stop-start.

If your uric acid is still above target on the highest dose you can tolerate, adding a second urate-lowering drug sounds like the obvious next step. The two main families lower urate in different ways. A xanthine oxidase inhibitor such as allopurinol turns down how much uric acid your body makes, while a uricosuric helps your kidneys flush more of it out⁵. On paper, doing both at once should get you further.

In practice, the guidelines are more cautious than that intuition. When a first xanthine oxidase inhibitor is maxed out and still not reaching target in someone with frequent flares or stubborn tophi, the American College of Rheumatology leans toward switching to a second inhibitor before reaching for a combination⁶. Combining two urate-lowering drugs is a real option, but it is usually not the first thing tried.

Part of the reason is history. The one drug designed specifically to be bolted onto a xanthine oxidase inhibitor was lesinurad, a uricosuric licensed only for use alongside one and capped at 200 mg a day because higher doses raised a kidney safety signal⁷. It has since been withdrawn from the US market by its manufacturer, though it technically remains FDA approved⁸. Probenecid, an older uricosuric that works on the same kidney transporter, is still available and is sometimes paired with an inhibitor.

For a small group of people, oral urate-lowering drugs have genuinely run out of road. When inhibitors and uricosurics have both failed to get someone to target, and they still have frequent flares or tophi that will not resolve, the guideline strongly recommends switching to pegloticase, an infused medicine that dissolves uric acid directly⁹.

Pegloticase has a well-known weakness: in many people the immune system learns to attack it, which blunts the drug and drives up infusion reactions. This is where the best-evidenced combination in all of gout comes in. In the MIRROR trial, adding methotrexate, a medicine that quiets the immune response, alongside pegloticase raised the share of people who reached their urate target from 38.5% to 71.0%, and cut infusion reactions from 30.6% to 4.2%¹⁰.

This is a specialist combination, several steps down the treatment path, and it sits with rheumatology rather than a family doctor. It is worth knowing about if you have been told nothing else works.

A treatment that is not getting you to target can look like a dead end. It rarely is.

The treat-to-target approach assumes some tools will fall short, and the plan adjusts when they do: a higher dose, a swap to a different drug, or two medicines covering gout's two separate jobs. The target does not move, but the route to it can¹.

If your current medicine is falling short, bring your latest urate number to your next appointment and ask what the next step is.